Élargissez vos compétences et découvrez le pouvoir transformationnel de la psychothérapie assistée par psychédélique.
Découvrir nos formations"Les produits psychédéliques pourraient être plus efficaces et avoir moins d'effets secondaires que les antidépresseurs”.
Les psychédéliques regroupent plusieurs substances psychoactives d'origine végétale, animale, ou synthétique. Ils sont largement reconnus pour leur haut potentiel de guérison dans le cadre d'une psychothérapie assistée par psychédélique pour le traitement de l’anxiété, de la dépression, de nombreuses dépendances, du trouble de stress post-traumatique, ou encore de la détresse anxio-dépressive de fin de vie. Ce grand potentiel thérapeutique représente à lui seul une révolution en cours dans le domaine de la santé mentale et du bien-être psychique.
L’agence gouvernementale américaine (Food and Drug Administration) chargée de protéger la santé publique a attribué le statut de thérapie révolutionnaire à ces 3 substances psychédéliques:
Utilisé pour l’accompagnement et le traitement de certaines dépressions.
Utilisé pour le traitement de l'anxiété, de plusieurs types de dépressions, dont la dépression sévère (dite "résistante" aux antidépresseurs), ou encore de l'anxiété de fin de vie.
Utilisé pour le traitement des addictions, des TOC (ex : troubles alimentaires) et de nombreux types de traumatismes (PTSD).
La recherche scientifique a démontré l'utilité, l'innocuité (le caractère sans danger) et l'extraordinaire efficacité des thérapies psychédéliques pour de nombreuses indications.
La PAP est une forme innovante de psychothérapie, intégrant l'utilisation d'une substance psychoactive comme la psilocybine, la kétamine, la MDMA ou encore le LSD. Elle permet d'induire une profonde expérience de reconnexion à soi-même, et à “plus grand que soi-même*”, facilitant ainsi une guérison transformatrice et durable.
(*) : source MAPS Canada.
ENTEA est une organisation à but non lucratif, de santé mentale et bien-être psychique offrant des modules de formation spécialisés, dans une perspective de pratique réglementée.
Découvrir nos formationsLe secteur des thérapies psychédéliques est en plein développement, en réponse à un besoin grandissant en matière de soins adaptés en santé mentale et bien-être psychique. Il représente une solution prometteuse face aux impacts sociaux, notamment liés aux enjeux environnementaux ou sanitaires, dans une perspective de légalisation progressive (cadre réglementaire en évolution).
Pour se structurer efficacement, ce nouveau domaine de pratique a avant tout besoin de praticiens formés, compétents et expérimentés, ouverts à accompagner leurs patients dans une nouvelle approche de soins personnalisés, supportée par un nouveau cadre psychothérapeutique.
des personnes ont reçu un dépistage positif de dépression majeure, de trouble d'anxiété, ou de stress post-traumatique (PTSD).
des personnes sont touchés par un problème de santé mentale à partir de 40 ans.
des personnes auraient une dépendance, à l'alcool, à certaines drogues et médicaments, et autres addictions.
Faciliter l'accès aux psychothérapies assistées par psychédéliques (PAP) en formant une communauté de praticiens multidisciplinaires.
Vision
Favoriser un processus transformateur, par les meilleurs moyens d'accompagnement psychothérapeutique, et une nouvelle génération de médicaments prometteurs.
Aan Het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ.
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant
depression. Biological Psychiatry. 2010 Jan 15;67(2):139-45.
Abbar M., et Col., “Ketamine for the acute treatment of severe suicidal ideation: double blind,
randomised placebo controlled trial”, BMJ, 2022, 376:e067194 http://dx.doi.org/10.1136/ bmj-2021-
067194
Abdallah C.G., et Col., « Ketamine’s mechanism of action: a path to rapid acting antidepressants”,
Depression and Anxiety, 2017, 33, 8, 689-697.
Abdallah C.G., et Col., «Dose-related effects ok ketamine for antidepressant-resistant symptoms of
posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized,
placebo—controlled multi-center clinical trial”, Neuropsychopharmacology, 2022, 47, 8, 1574-1581.
Adams TG, Bloch MH, Pittenger C. Intranasal ketamine and cognitive-behavioral therapy for
treatment-refractory obsessive-compulsive disorder. J Clin Psychopharmacol. 2017;37(2):269–271.
doi:10.1097/JCP.0000000000000659
Adler CM, Malhotra AK, Elman I, Goldberg T, Egan M, Pickar D, et al. Comparison of ketamine-
induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J
Psychiatry. 1999 Oct;156(10):1646– 9.
Albott CS, Shiroma PR, Cullen KR, Johns B, Thuras P, Wels J, et al. The Antidepressant Effect of Repeat
Dose Intravenous Ketamine Is Delayed by Concurrent Benzodiazepine Use. J Clin Psychiatry. 2017
Mar;78(3):e308–9.
Albott C, Lim KO, Forbes MK, Erbes C, Tye SJ, Grabowski JG, et al. Efficacy, safety, and
durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and
treatment-resistant depression. J Clin Psychiatry,2018; 79(3): 17m11634
Anand A. et Col., “Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major
Depression”, 2023 May 24, N Engl J Med, doi: 10.1056/NEJMoa2302399.
Arabzadeh S., et Col., “ Does oral administration ok ketamine accelerate response to
treatment on major depressive disorder? Results of a double-blind controlled trial”, Journal of
Affective Disorders, 235, 236-241.
Archer S., et Col., “Maintenance Ketamine Therapy for Treatment-Resistant Depression”,
2018, Journal of Clinical Psychopharmacology, 38, 4, 380-384.
Aust S., et Col., “Anxiety during ketamine infusions is associated with negative treatment
responses in major depressive disorder”, 2019, Eur Neuropsychopharmacol., 29, 529-538.
Azhari N, Hu H, O’Malley KY, Blocker ME, Levin FR, Dakwar E. Ketamine-facilitated behavioral
treatment for cannabis use disorder: a proof of concept study. Am J Drug Alcohol Abuse.
2021;47(1):92–97. doi:10.1080/00952990.2020.1808982
Aziz W, Babb C, Brown D, Exeer AM, Manalai P., “Ketamine Role in Schizoaffective Disorder
Depressive Type”, 2017, J Addict Res Ther, 8, 5, 346. DOI: 10.4172/2155-6105.1000346
Bahji A, Vazquez GH, Zarate CA Jr. , “Comparative efficacy of racemic ketamine and
esketamine for depression: A systematic review and meta-analysis “, J Affect Disord. 2021
Feb 15;281:1001. doi: 10.1016/j.jad.2020.11.103. Epub 2020 Nov 20. PMID: 33229028
Ballard ED, Wills K, Lally N, et al. “Anhedonia as a clinical correlate of suicidal thoughts in
clinical ketamine trials”, J Affect Disord, 2017;218: 195–200
Ballard ED, Zarate CA Jr. The role of dissociation in ketamine’s antidepressant effects. Nat Commun.
(2020) 11:6431. doi: 10.1038/s41467-020-20190-4
Bartoli F et al., « Ketamine as a rapid-acting agent for suicidal ideation: A meta-analysis”
2017, Neurosci Biobehav Rev., 77, 232-236.
Bartoli F, Clerici M, Carrà G., “Antidepressant response and dissociative effects after ketamine
treatment: two sides of the same coin?”, 2017, J Clin Psychiatry, 78, 9, e1318
Bauereiss N, Obermaier S, Ozunal SE et al (2018) Effects of existential interventions on spiritual,
psychological, and physical well-being in adult patients with cancer: systematic review and meta-
analysis of randomized controlled trials. Psychooncology 27(11):2531–2545.
Becker J., “Regarding the transpersonal nature of ketamine therapy: an approach to the work”, Int J
Transpers Stud., 2014;33(2):151–159. doi:10.24972/ijts.2014.33.2.151
Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH.,
“Antidepressant effects of ketamine in depressed patients”, 2000, Biological Psychiatry, 47, 4,
351-354.
Bloch M., et Col., “Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive
Disorder”, 2012, Biol Psychiatry, 72, 11, 964–970.
Blonk MI, Koder BG, van den Bemt PMLA et al (2010) Use of oral ketamine in chronic pain
management: a review. Eur J Pain 14(5):466–472
Bonhomme V., et Col., “Resting-state network-specific breakdown of functional connectivity
during ketamine alteration of consciousness in volunteers”, 2016, Anesthesiology; 125, 5,
873-888.
Bottemanne H, Claret A, Fossati P. Kétamine et autres psychotropes. In Millet B, Vanelle JM, Prescrire
les psychotropes, 2nd édition. Paris: Elsevier Masson. 2020a.
Bottemanne H, Claret A, Fossati P. [Ketamine, psilocybin, and rapid acting antidepressant: new
promise for psychiatry?]. Encephale. 2020b Nov 12, DOI:10.1016/j.encep.2020.08.006
Bottemanne H, Bonnard E, Claret A, Petit A-C, Gaillard R, Fossati P. Ketamine and Monoamine
Oxidase Inhibitor Combination: Utility, Safety, Efficacy? J Clin Psychopharmacol. 2020c
Dec;40(6):636–8.
Bottemanne H, Morlaàs O, Claret A, Fossati P, Schmidt L. Can we change depressive beliefs?
Modulation of belief updating by ketamine in treatment resistant depression. PsyArXiv; 2021.
Bottemanne H., et Col., “Psychothérapie augmentée par la kétamine (KAP) dans les troubles
de l’humeur : mode d’emploi », 2022, L’encéphale, 48, 3, 304-312.
Braithwaite JJ, James K, Dewe H, Medford N, Takahashi C, Kessler K. Fractionating the unitary notion
of dissociation: disembodied but not embodied dissociative experiences are associated with
exocentric perspective-taking. Front Hum Neurosci. 2013;7:719.
Bravo G., Grant R., Bennett R., “Ketamine”, In Grob C., Grigsby J. (Eds.), “Handbook of
Medical Hallucinogens”, 2021, Guilford Press.
Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, et al.,
« Measurement of dissociative states with the Clinician-Administered Dissociative States
Scale (CADSS) », 1998, J Trauma Stress, 11, 1, 125–136.
Browne C.A., Lucki I., “Antidepressant effects of ketamine: mechanisms underlying fast-
acting novel antidepressants”, Front. Pharmacol. 2013; 4: 161.
Canuso C., et Col., “Efficacy and safety of intranasal esketamine for the rapid reduction of
symptoms of depression and suicidality in patients at imminent risk for suicide: Results of a
double-blind, randomized, placebo-controlled study”, 2018, Am J Psychiatry, 175, 7, 620-630.
Carhart-Harris RL, Goodwin GM. The Therapeutic Potential of Psychedelic Drugs: Past, Present, and
Future. Neuropsychopharmacology. 2017 Oct;42(11):2105–13.
Castillo A., et Col., “Measuring acute effects of subanesthetic ketamine on cerebrovascular
hemodynamics using TD-fNIRS”, 2023, Scientific Reports, 13, Article Number 11665.
Chen IC, Lee MH, Chen WC et al (2018) Risk factors of lower urinary tract syndrome among ketamine
users. Low Urin Tract Symptoms 10(3):281–286
Chilukuri, H., R. Pothula, R. Pathapati, A. Manu, S. Jollu, and A. Shaik, “Acute antidepressant
effects of intramuscular versus intravenous ketamine”, 2014, Indian Journal of Psychological
Medicine, 36, 1, 71–76.
Collins, K., J. Murrough, A. Perez, D. Reich, D. Charney, and S. Mathew, “ Safety and efficacy
of repeated-dose intravenous ketamine for treatment-resistant depression”, 2010, Biological
Psychiatry, 67, 2, 139–45.
Conley AA, Norwood AEQ, Hatvany TC, Griffith JD, Barber KE. Efficacy of ketamine for major
depressive episodes at 2, 4, and 6-weeks post-treatment: A meta-analysis. Psychopharmacology
(Berl). 2021 Mar 31;
Corlett PR, Honey GD, Fletcher PC. Prediction error, ketamine and psychosis: An updated model. J
Psychopharmacol. 2016 Nov;30(11):1145–55.
Corssen G., Domino E., “Dissociative anesthesia : further pharmacologic studies and first
clinical experience with the phencyclidine derivative CI-581”, Anesthesia & Analgesia, 1966,
45, 29-40.
Cui Y., et Col., “Lateral habenular burst firing as a target of the rapid antidepressant effects
of ketamine”, Trends in Neurosciences, 2019, 42, 3, 179-191.
Cusin, C., G. Hilton, A. Nierenberg, and M. Fava. 2012. Long-term maintenance with
intramuscular ketamine for treatment-resistant bipolar II depression. American Journal of
Psychiatry 169:868–69. doi:10.1176/appi.ajp.2012.12020219
Cusin G., et Col., “Ketamine augmentation for outpatients with treatment-resistant
depression: Preliminary evidence for two-step intravenous dose escalation”, 2017, Australian
and New Zealand Journal of Psychiatry, 51, 55-64.
Dadiomov D, Lee K., “The effects of ketamine on suicidality across various formulations and study
settings”, Ment Health Clin 2019; 9, 1: 48–60
Dakwar E., et Col., “The effects of sub-anesthesic ketamine infusions on motivation to quit
and cue-induced craving in cocaine-dependent research volunteers”, 2014a, Biol. Psychiatry,
76, 40-46.
Dakwar E., et Col., “Therapeutic infusions of ketamine: Do the psychoactive effects matter?”,
2014b, Drug Alcohol Depend”, 136, 153-157.
Dakwar E., et Col., “Cocaine self-administration disrupted by the N-methyl-D-aspartate
receptor antagonist ketamine: a randomized, crossover trial”, 2017, Mol. Psychiatry, 22, 76-
81. https://doi.org/10.1038/mp.2016.39
Dakwar E., et Col., “A sub-set of psychoactive effects may be critical to the behavioral impact
of ketamine on cocaine use disorder: results from a randomized, controlled laboratory
study”, 2018 Nov, Neuropharmacology, 142, 270-276.
Dakwar E. et Col., « A Single Ketamine Infusion Combined With Mindfulness-Based
Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial”, 2019,
American Journal of Psychiatry, 176, 11; doi: 10.1176/appi.ajp.2019.18101123.
Dakwar E. et Col., « A Single Ketamine Infusion Combined With motivational enhancement
therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial”, 2020, Am. J.
Psychiatry, 177, 125-133.
Daly E. et Col., “Efficacy and safety of intranasal esketamine adjunctive to oral
antidepressant therapy in treatment resistant depression”: A randomized clinical trial”, 2018,
Journal of the American Medical Association Psychiatry, 75, 2, 139-148.
Daly E., et Col., “ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for
Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical
Trial”, 2019, JAMA Psychiatry, 76, 9, 893-903.
Davis, A.K.; Mangini, P.; Xin, Y. Ketamine-Assisted Psychotherapy for Trauma-Exposed Patients in an
Outpatient Setting: A Clinical Chart Review Study. J. Psychedelic Stud. 2021, 5, 94–102. [CrossRef
Dechant, E.; Boyle, B.; Ross, R.A. Ketamine in a Patient with Comorbid Anorexia and MDD. J.
Women’s Health Dev. 2020, 3, 373–375. [CrossRef]
Deyama S et al. , “Role of neuronal VEGF signaling in the prefrontal cortex in the rapid
antidepressant effects of ketamine”, 2019, Am J Psychiatry, 176, 5, 388-400.
Deyama S., Duman RS., “Neurotrophic mechanism underlying the rapid and sustained
antidepressant actions of ketamine”, 2020, Pharmacol Biochem Behav., 188: 172837.
Diamond P., et Col., “ketamine infusions for treatment resistant depression: A series of 28
patients treated weekly or twice weekly in an ECT clinic”, 2014, Journal of
Psychopharmacology, 28, 6, 536-544.
Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA,
Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA Jr., “A
randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant
bipolar depression”, 2010, Archives of General Psychiatry, 67, 8, 793-802.
Domino E., et Col., “Pharmacologic effects of ci-581, new dissociative anesthesic in man”,
1965, Clin. Pharmacol. Ther., 6, 279-291.
Domino E., « Taming the ketamine Tiger”; 2010, Anesthesiology, 113, 678-686.
Dore J., et Col., “Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data
and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy”, 2019,
Journal of Psychoactive Drugs, 51, 2, 189-198.
Du J, Machado-Vieira R, Maeng S, et al., “Enhancing AMPA to NMDA throughput as a
convergent mechanism for antidepressant action”, Drug Discov Today Ther Strateg, 2006, 3,
519–526.
Duek O., et Col., « Augmenting the treatment of PTSD with Ketamine-a Review”, 2019, Curr
Treat Options Psychiatr., 6, 2, 143-153.
Duman RS, et Col., “Signaling pathways underlying the rapid antidepressant actions of
ketamine”, 2012, Neuropharmacology, 62, 35-41
Duman, R. S., Aghajanian, G. K., Sanacora, G. & Krystal, J. H. “Synaptic plasticity and
depression: new insights from stress and rapid-acting antidepressants” 2016, Nat. Med. 22,3,
238–249.
Duncan G. et Col., “ Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in
Older Patients with Treatment-Resistant Depression”, 2017, The American Journal of
Geriatric Psychiatry, 25, 11, 1199-1209DOI: 10.1016/j.jagp.2017.06.007
Early T., “ Making ketamine work in the long run”, 2014, International Journal of
Transpersonal Studies, 33, 2, 141-150.
Early, T., “Making ketamine work in the long run”. In: The ketamine papers: Science,therapy
and transformation, ed. P. Wolfson and G. Hartellius, 2016, 305–22. Santa Cruz, CA: MAPS
Press
Ebert, B.; Mikkelsen, S.; Thorkildsen, C.; Borgbjerg, F.M. Norketamine, the Main Metabolite of
Ketamine, Is a Non-Competitive NMDA Receptor Antagonist in the Rat Cortex and Spinal Cord. Eur. J.
Pharmacol. 1997, 333, 99–104. [CrossRef]
Evans JW et al., “Default Mode Connectivity in Major Depressive Disorder Measured Up to 10
Days After Ketamine Administration”, 2018, Biological Psychiatry, 84, 8, 582-590.
Ezquerra-Romano I., Lawn W., Krupitsky E., Morgan C., «Ketamine for the treatment of
addiction: Evidence and potential mechanisms”, 2018, Neuropharmacology, 142:72-82.
Falk E, Schlieper D, Van Caster P, et al. (2020) A rapid positive infuence of S-ketamine on the anxiety
of patients in palliative care: a retrospective pilot study. BMC Palliative Care 19(1)
Fan W, Yang H, Sun Y et al (2017) Ketamine rapidly relieves acute suicidal ideation in cancer patients:
a randomized controlled clinical trial. Oncotarget 8(2):2356–2360
Fattore L., et Col., “Psychedelics and reconsolidation of traumatic and appetitive maladaptive
memories: focus on cannabinoids and ketamine”, 2018, Psychopharmacology, 235, 2, 433-
445.
Fava M., et Col., “Double-blind, placebo-controlled, dose-ranging trial of intravenous
ketamine as adjunctive therapy in treatment-resistant depression (TRD)”, 2020, Molecular
Psychiatry, 25, 7, 1592-1603.
FDA Briefing Document (2019). Psychopharmacologic Drugs Advisory Committee (PDAC) and
Drug Safety and Risk Management (DSaRM) Advisory Committee Meeting. Retrieved March
13, 2019, from www.fda.gov/committees-
meetingmaterials/drugs/psychopharmacologicdrugsadvisorycommittee/ucm630970.pdf.
Fedgchin M. et al., « Etude randomisée, contrôlée en double aveugle, comparant des doses
fixes d’eskétamine intranasale avec association d’un antidépresseur oral à un comparateur
actif dans la dépression résistante au traitement », International Journal of
Neuropsychopharmacology (étude TRANSFORM 1), 2019, Published by Oxford University
Press on behalf of CINP. Document transmis sur demande par les laboratoires Janssen.
Feder A et al., “Efficacy of intravenous ketamine for treatment of chronic posttraumatic
stress disorder: A randomised clinical trial”, 2014, JAMA Psychiatry, 71, 6, 681-688.
Ferreira, S.R., Machado, A.R.T., Furtado, L.F. et al. Ketamine can be produced by Pochonia
chlamydosporia: an old molecule and a new anthelmintic?. Parasites Vectors 13, 527 (2020).
https://doi.org/10.1186/s13071-020-04402-w
Fond G, Loundou A, Rabu C, Macgregor A, Lançon C, Brittner M, et al. “Ketamine
administration in depressive disorders: a systematic review and meta-analysis”.
Psychopharmacol Bull 2014; 231(18): 3663–76.
Fontana A.E., « Clinical use of hallucinogenic drugs », In: Proceedings of the Third World
Congress of Psychiatry, 1963, Vol.2: 942-944, Toronto, University of Toronto Press.
Fontana A. E., Loschi J. A., « Antidepressive therapy with CI 581”, 1974, Acta Psychiatr. Psicol.
Am. Lat., 20, 32-39.
Gálvez V., et Col., “Repeated intranasal ketamine for treatment-resistant depression – the
way to go? Results from a pilot randomised controlled trial”. 2018, Journal of
Psychopharmacology, 32, 4, 397-407.
Ghasemi M., et Col., “Rapid antidepressant effects of repeated doses of ketamine compared
with electroconvulsive therapy in hospitalized patients with major depressive disorder”, 2014,
Psychiatry Research, 215, 355-361.
Glue P., et Col., “Dose- and exposure-response to ketamine in depression”, 2011, Biological
Psychiatry, 70, 4, e9-e10.
Glue P, Medlicott NJ, Harland S, Neehoff S, Anderson-Fahey B, Le Nedelec M, et al.,” Ketamine’s
dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders”, J
Psychopharmacol 2017; 31(10): 1302–5.
Glue P. et Col., « Safety and efficacy of maintenance ketamine treatment in patients with
treatment-refractory generalised anxiety and social anxiety disorders”, 2018, J
Psychopharmacol., 32, 6, 663-667. doi: 10.1177/0269881118762073.
Glue P, Neehoff S, Sabadel A, Broughton L, Le Nedelec M, Shadli S, et al. Effects of ketamine
in patients with treatment-refractory generalized anxiety and social anxiety disorders:
exploratory double-blind psychoactive-controlled replication study. J Psychopharmacol
2019; 34(3): 267–72.
Goldman N, Frankenthaler M and Klepacz L (2019), “The efficacy of ketamine in the palliative
care setting: a comprehensive review of the literature”, J Palliat Med, 1154–1161.
Grabski M, Borissova A, Marsh B, Morgan CJ, Curran HV. Ketamine as a mental health
treatment: are acute psychoactive effects associated with outcomes? A systematic review.
Behav Brain Res 2020; 392: 112629
Grabski M., et Col., “Adjunctive ketamine with relapse prevention-based psychological
therapy in the treatment of alcohol use disorder”, 2022, Am. J. Psychiatry, 179, 152-162.
Green S., Johnson N., “Ketamine sedation for pediatric procedures: Part 2, review and
implications”, Annals of Emergency Medicine, 1990, 19, 1033-1046.
Grof L., “Quand l’impossible arrive », Guy Trédaniel Editeur, 2007, p. 286-293,
chapitre « Matière et conscience-La kétamine et le réenchantement du monde ».
Grunebaum MF, et al, “Ketamine versus midazolam in bipolar depression with suicidal
thoughts: A pilot midazolam-controlled randomized clinical trial”, Bipolar Disord,, 2017,
19:176-83. doi:10.1111/bdi.12487 pmid:28452409
Grunebaum MF, Galfalvy HC, Choo TH, et al., “Ketamine for rapid reduction of suicidal
thoughts in major depression: a midazolam-controlled randomized clinical trial”, 2018, Am J
Psychiatry, 175, 4, 327-335.
Halstead, M.; Reed, S.; Krause, R.; Williams, M.T. Ketamine-Assisted Psychotherapy for PTSD Related
to Racial Discrimination. Clin. Case Stud. 2021, 20, 310–330. [CrossRef]
Hamilton JP et al., “Depressive Rumination, the Default-Mode Network, and the Dark Matter
of Clinical Neuroscience”, 2015, Biological Psychiatry, 78, 4, 224–230.
Harmer C, Duman RS, Cowen PJ. “How do antidepressants work? New perspectives for
refining future treatment approaches”. Lancet Psychiatry 2017; 4(5): 409–18
Hartberg J. et Col., “Impact of oral ketamine augmentation on hospital admissions in
treatment-resistant depression and PTSD: A retrospective study”, 2018,
Psychopharmacology, 253, 2, 393-398.
Hashimoto K., “Emerging role of glutamate in the pathophysiology of major depressive
disorder”, 2009, Brain Research Review, 61, 2, 105-123.
Hasler G., “Toward specific ways to combine ketamine and psychotherapy in treating
depression”, CNS Spectrums, 2020, 445–447.
Hasler G, Suker S, Schoretsanitis G, Mihov Y. Sustained Improvement of Negative Self-Schema After a
Single Ketamine Infusion: An Open-Label Study. Front Neurosci. 2020b;14:687.
Heifets B., et Col., Disruptive Psychopharmacology », JAMA Psychiatry, Published online June
26, 2019. doi:10.1001/jamapsychiatry.2019.1145.
Holbrook TL., et Col., « Morphine use after combat injury in Iraq and post-traumatic stress
disorder”, 2010, N Engl J Med., 362, 2, 110-117.
Hu Y. et Col., « Single i.v. ketamine augmentation of newly initiated escitalopram for major
depression: Results from a randomized, placebo-controlled 4-week study”, 2016,
Psychological Medicine, 46, 3, 623-635.
Huge V. et Col., « Effects of low-dose intranasal (S)-ketamine in patients with neuropathic
pain”, Eur J Pain, 2010 Apr;14(4):387-94. doi: 10.1016/j.ejpain.2009.08.002. Epub 2009
Sep 3.
Hull T.D., et Col., “At-Home, sublingual ketamine telehealth is a safe and effective treatment
for moderate to severe anxiety and depression: findings from a large, prospective, open-label
effectiveness trial”, Journal of Affective Disorders, 2022, 314, 59-67.
Hyde S. J. 2015. Ketamine and depression. Tasmania: Xlibris
Hyde S., “Sustainable Ketamine Therapy”, In Wolfson, P., and G. Hartelius, editors, “The
ketamine papers”, 2016, Santa Cruz, CA: MAPS.
Iglewicz A., et Col., “Ketamine for the treatment of depression in patients receiving hospice
care: A retrospective medical record review of thirty one cases”, 2015, Psychosomatics, 56, 4,
329-337.
Ionescu D., et Col., “Repeated-dose ketamine augmentation for treatment-resistant
depression with chronic suicidal ideation: A randomized, double-blind placebo controlled
trial”, 2019, Journal of Affective Disorders, 243, 516-524.
Irwin S.A., & Iglewicz A., “Oral ketamine for the rapid treatment of depression and anxiety in
patients receiving hospice care”, 2010, Journal of Palliative Medicine, 13, 7, 903-908.
Irwin S.A., et Col., « Daily oral ketamine for the treatment of depression and anxiety in
patients receiving hospice care: a 28-day open-label proof of concept trial”, Journal of
palliative Medicine, 2013, 16, 8, 958-965.
Ivan-Ezquerra-Romano I., et Col., « Ketamine for the treatment of addiction: Evidence and
potential mechanisms”, 2018, Neuropharmacology, 142, 72-82.
Jafarinia M., et Col., “Efficacy and safety of oral ketamine versus diclofenac to alleviate mild
to moderate depression in chronic pain patients: A double-blind, randomized, controlled
trial”, 2016, Journal of Affective Disorders, 204, 1-8.
Jaitly V., “Sublingual ketamine in chronic pain: Service evaluation by examining more than
200 patient years of data”, 2013, Journal of Observational Pain Medicine, 1/2.
Jansen K., “Using ketamine to induce the near-death experience: Mechanism of action and
therapeutic potential”, 1995, Yearbook for Ethnomedicine and the Study of Consciousness, 4, 55-79.
Jansen K., "Ketamine: Dreams and Reality", 2004, MAPS, Second Edition.
Jantzen J.P., et Col., “Comparative study of analgesia and plasma level following rectal,
intramuscular and intravenous administration of ketamine”, Anaesthesist, 1985 Jul;34(7):346-51.
Jones J. et Col., “Efficacy of Ketamine in the Treatment of Substance Use Disorders: A
Systematic Review”, 2018, Frontiers in Psychiatry, 9, 277.
Jovaisa T. et Col., « Effects of ketamine on precipitated opiate withdrawal-Effets de la
kétamine sur le retrait précipité d'opiacé »2006, Medicina (Kaunas), 42, 8, 625-634.
Keizer BM, Roache JD, Jones JR, Kalpinski RJ, Porcerelli JH, Krystal JH. Continuous ketamine infusion
for pain as an opportunity for psychotherapy for PTSD: a case series of ketamine-enhanced
psychotherapy for PTSD and pain (KEP-P2). Psychother Psychosom. 2020;89(5):326–329.
doi:10.1159/000507095
Kishimoto, T.; Chawla, J.M.; Hagi, K.; Zarate, C.A.; Kane, J.M.; Bauer, M.; Correll, C.U. Single-Dose
Infusion Ketamine and Non-Ketamine N-Methyl-d-Aspartate Receptor Antagonists for Unipolar and
Bipolar Depression: A Meta-Analysis of Efficacy, Safety and Time Trajectories. Psychol. Med. 2016,
46, 1459–1472. [CrossRef]
Koffler et Col., «The neurocognitive effects of 5 day anesthesic ketamine for the treatment of
refractory complex regional pain syndrome”, 2007, Archives of Clinical Neuropsychology, 22,
719-729.
Kolp E., et Col., « Ketamine enhanced psychotherapy : Preliminary clinical observations on its
effectiveness in treating alcoholism” , 2006, The Humanistic Psychologist, 34, 399-422.
Kolp E, Krupitsky E, Young MS, Jansen K, Friedman H, O’Connor LA., “Ketamine-enhanced
psychotherapy: preliminary clinical observations on its effects in treating death anxiety”,
2007, Int J Transpersonal Stud., 26,1–17.
Kolp E., Krupitsky E., et Col., « Entheogen-enhanced transpersonal psychotherapy of
addictions: Focus on clinical applications of ketamine for treating alcoholism”, 2009, In
A.Browne-Miller (Ed.), The Praeger International Collection on Addictions, 3, 403-417.
Kolp E., et Col., “Ketamine Psychedelic Psychotherapy : Focus on its Pharmacology,
Phenomenology, and Clinical Applications”, 2014, Int J Transpers Stud., 33, 2, 84-140.
Kolp E., et Col., “Ketamine Psychedelic Psychotherapy : Focus on its Pharmacology,
Phenomenology, and Clinical Applications”, 2016, In Wolfson, P., and G. Hartelius, editors,
“The ketamine papers”, 2016, Santa Cruz, CA: MAPS.
Khorramzadeh E., Lofty A.O., « The use of Ketamine In Psychiatry », 1973, Psychosomatic
Journal, November-December, 14:344-346.
Krupitsky E., et Col., “The combination of psychedelic and aversive approaches in alcoholism
treatment”, 1992, Alcohol. Treat. Q., 9, 99-105.
Krupitsky E., “Ketamine psychedelic Therapy (KPT) of alcoholism and neurosis”, 2012, MAPS
Newsl., 3, 24-28.
Krupitsky, E., Grinenko, A., “Ketamine psychedelic therapy (KPT): A Review of the Results of
Ten Years of Research », 1997, Journal of Psychoactive Drugs, 29, 2, 165-183.
Krupitsky, E.M.; Burakov, A.M.; Romanova, T.N.; Dunaevsky, I.V.; Grinenko, A.Y. Ketamine Assisted
Psychotherapy (KPT) of Heroin Addiction: Immediate Effects and Six Months Followup. MAPS Bull.
2001, 9, 21–26
Krupitsky E, Burakov, A, Romanova, T, Dunaevsky, I, Strassman, R, Grinenko A (2002).
“Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up »,
2002, Journal of Substance Abuse Treatment, 23, 273-283.
Krupitsky, EM, Burakof AM, Dunaevsky IV, Romanova TN, Slavina TY, Grinenko AY, “Single
Versus Repeated Sessions of Ketamine-Assisted Psychotherapy for People with Heroin
Dependence”, 2007, Journal of Psychoactive Drugs, 39, 1: 13-19.
Krupitsky E., Kolp E., “Ketamine psychedelic psychotherapy”, In M.J. Winkelman & T.Roberts
(Eds.) , Psychedelic medicine: New evidence for hallucinogenic substances as treatments (Vol.
2, pp. 67-85), Wesport, CT: Praeger/Greenwood.
Krystal, J. H., L. P. Karper, J. P. Seibyl, G. K. Freeman, R. Delaney, J. D. Bremner, and D. S.
Charney, “ Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in
humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses”, 1994,
Archives of General Psychiatry 51, 3, 199–214.
Krystal, J. H., “Ketamine and the potential role for rapid-acting antidepressant medications”,
2007, Swiss Medical Weekly 137, 15–16, 215–216.
Krystal JH, Abdallah CG, Sanacora G, et al. “Ketamine: a paradigm shift for depression
research and treatment”, Neuron. 2019;101, 5, 774–778
Kryst J, Kawalec P, Mitoraj AM, Pilc A, Lasoń W, Brzostek T. Efficacy of single and repeated
administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical
trials. Pharmacol Rep. 2020;72(3):543–62.
Kungurtsev, I. , “Death-Rebirth psychotherapy with ketamine”. The Albert Hofmann
Foundation, 1991, 2, 1-6 (California).
Lapidus K., et Col., “A Randomized Controlled Trial of Intranasal Ketamine in Major
Depressive Disorder”, 2014, Biological Psychiatry, 76, 12, 970-976.
Lara, D., L. Bisol, and L. Munari, “ Antidepressant, mood stabilizing and procognitive effects
of very low dose sublingual ketamine in refractory unipolar and bipolar depression”, 2013,
The International Journal of Neuropsychopharmacology, 16 , 9, 2111–2117.
Lassale J., “The ketamine handbook-A beginner’s guide to ketamine assisted therapy for
depression, anxiety, trauma, PTSD, and more”, Ulysses Press, 2023.,
Lee Y et al., “A New Perspective on the Anti-Suicide Effects With Ketamine Treatment: A
Procognitive Effect”, 2016, J Clin Psychopharmacol., 36, 1, 50-56.
LeMay K, Wilson KG (2008) Treatment of existential distress in life threatening illness: a review of
manualized interventions. Clin Psychol Rev 28(3):472–493
Li N. et Col.., “mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant
Effects of NMDA Antagonists”, 2010, Science, 329, 5994, 959-964.
Lilly J., “The Scientist: A Metaphysical Autobiography”, 1988, Ronin Publishing.
Liu P, Li P, Li Q et al (2020) Effect of pretreatment of S-ketamine on postoperative depression for
breast cancer patients. J Invest Surg. https://doi.org/10.1080/08941939.2019.1710626
Loo C., et Col., “Placebo-controlled pilot trial testing dose titration and intravenous,
intramuscular and subcutaneous routes for ketamine in depression”, 2016, Acta Psychiatrica
Scandinavica, 134, 1, 48-56.
Luckenbaugh, D. A., M. J. Niciu, D. F. Ionescu, N. M. Nolan, E. M. Richards, N. E. Brutsche, and
C. Zarate, “Do the dissociative side effects of ketamine mediate antidepressant effects”,
2014, Journal of Affective Disorders, 159, 56–61.
Lv Q et al., « Large-scale persistent network reconfiguration induced by ketamine in
anesthetized monkeys: relevance to mood disorders”, 2016, Biol Psychiatry, 79, 9, 765-775.
Ly C., et Col. , “Psychedelics Promote Structural and Functional Neural Plasticity”, 2018, Cell
Reports, 23, 11, 3170-3182.
Mak SK, Chan MT, Bower WF et al (2011) Lower urinary tract changes in young adults using
ketamine. J Urol 186(2):610–614
Martial C., et Col., « Neurochemical models of near-death experiences: A large-scale study
based on the semantic similarity of written reports”, Consciousness and Cognition, 2019, 69,
52-69.
Mathai D., et Col., « Revisiting the hallucinogenic potential of ketamine: A case built on
current research findings”, 2018, Psychiatric Times, 35. Retrieved from
www.psychiatrictimes.com/view/revisiting-hallucinogenic-potential-ketamine.
Mathai DS, Meyer MJ, Storch EA et al (2020) The relationship between subjective effects induced by
a single dose of ketamine and treatment response in patients with major depressive disorder: a
systematic review. J Affect Disord 264:123–129
Mathai D., et Col., « Toward Synergies of Ketamine and Psychotherapy”, Front. Psychol.,
2022, Volume 13, Article 868103.
McAndrew A. et Col., “A proof-of-concept investigation into ketamine as a pharmacological
treatment for alcohol dependence: study protocol for a randomised controlled trial”, 2017,
Trials,18,159. DOI 10.1186/s13063-017-1895-6.
McGhee L, Maani CV, Garza TH, Gaylord KM, Black IH. The correlation between ketamine
and posttraumatic stress disorder in burned service members. J Trauma Acute Care Surg
2008; 64(2): 195–199.
McGirr A et al., « A systematic review and meta-analysis of randomized, double-blind,
placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes”,
2015, Psychol Med. 2015, 45, 4, 693-704.
McInnes LA, Qian JJ, Gargeya RS, DeBattista C, Heifets BD. A retrospective analysis of ketamine
intravenous therapy for depression in real-world care settings. J Affect Disord. (2022) 301:486–95.
doi: 10.1016/j.jad.2021.12.097
McIntyre R, Carvalho IP, Lui L, Majeed A, Masand PS, Gill H, et al. The effect of intravenous,
intranasal, and oral ketamine in mood disorders: a meta-analysis. J Affect Disord 2020; 276:
576–584
McMullen, E.P.; Lee, Y.; Lipsitz, O.; Lui, L.M.W.; Vinberg, M.; Ho, R.; Rodrigues, N.B.; Rosenblat, J.D.;
Cao, B.; Gill, H.; et al. Strategies to Prolong Ketamine’s Efficacy in Adults with Treatment-Resistant
Depression. Adv. Ther. 2021, 38, 2795–2820. [CrossRef]
McNaughton N, Glue P., “Ketamine and neuroticism: a double-hit hypothesis of internalizing
disorders”, Personal Neurosci, 2020; 3: e2
Messer M. et Col., “The use of a series of ketamine infusions in two patients with treatment-
resistant depression”, 2010, J Neuropsychiatry Clin Neurosci., 22 ,4, 442-444.
Messer M. & Haller I., “Maintenance ketamine treatment produces long-term recovery from
depression”, 2013, Primary Psychiatry, 17, 4, 48-50.
Millière, R., R. Carhart-Harris, L. Roseman, F. Trautwein, and A. Berkovich-Ohana,
“Psychedelics, meditation, and self-consciousness”, 2018, Frontiers in Psychology, 9, 1475.
doi: 10.3389/fpsyg.2018.01475.
Mills I, Park GR, Manara AR, Merriman RJ., “Treatment of compulsive behaviour in eating disorders
with intermittent ketamine infusions”, QJM, 1998; 91, 7, 493–503
Mion, G.; Villevieille, T. Ketamine Pharmacology: An Update (Pharmacodynamics and Molecular
Aspects, Recent Findings). CNS Neurosci. Ther. 2013, 19, 370–380. [CrossRef]
Monteggia L., “The role of eEF2 kinase in rapid antidepressant action of ketamine”, Biol Psychiatry.
2013 Jun 15; 73(12): 1199–1203.
Moore M., Alltounian H., “Journeys into the Bright World”, 1978, Massachusetts: Para
Research, Inc.
Murrough JW, Iosifescu DV, Chang LC, et al.: “Antidepressant efficacy of ketamine in
treatment-resistant major depression: a two-site randomized controlled trial”, 2013, Am J
Psychiatry, 170, 10, 1134–1142
Murrough J., et Col., “Rapid and longer-term antidepressant effects of repeated ketamine
infusions in treatment-resistant major depression”, 2013b, Biological Psychiatry, 74, 4, 250-
256.
Murrough J., et Col., “Neurocognitive effects of ketamine in treatment-resistant major
depression: Association with antidepressant response”, 2014, Psychopharmacology, 231,
481-488.
Murrough J. et Col., “Ketamine for rapid reduction of suicidal ideation: a randomized
controlled trial”, 2015, Psychological Medicine, 45, 16, 3571-3580.
Murrough J. et Col., “Neurocognitive effects of ketamine and association with antidepressant
response in individuals with treatment-resistant depression: A randomized controlled trial”,
2015b, Neuropsychopharmacology, 40, 5, 1084-1090.
Murrough J. et Col., “ketamine for rapid reduction of suicidal ideation: A randomized
controlled trial”, 2015c, Psychological Medicine, 45, 3571-3580.
Newport, D.J.; Carpenter, L.L.; McDonald, W.M.; Potash, J.B.; Tohen, M.; Nemeroff, C.B.; APA Council
of Research Task Force on Novel Biomarkers and Treatments. Ketamine and Other NMDA
Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. Am. J. Psychiatry 2015, 172,
950–966. [CrossRef]
Nguyen L., et Col., “Off-label use of transmucosal ketamine as a rapid-acting antidepressant:
A retrospective chart review”, 2015, Neuropsychiatric Disease & Treatment, 14, 11, 2667-
2673.
Niciu M., et Col., “Features of dissociation differentially predict antidepressant response to
ketamine in treatment-resistant depression”, 2018, Journal of affective Disorders, 232, 310-
315.
Noppers I, Niesters M, Aarts L, Smith T, Sarton E, Dahan A. Ketamine for the treatment of chronic
non-cancer pain. Expert Opin Pharmacother. 2010;11(14):2417–2429.
doi:10.1517/14656566.2010.515978
Nour MM, Evans L, Nutt D, Carhart-Harris RL. Ego-dissolution and psychedelics: validation of the Ego-
dissolution inventory (EDI). Front Hum Neurosci. (2016) 10:269. doi: 10.3389/fnhum.2016.00269
Nutt D., King L., Philips L., “Drug harms in the UK: a multicriteria decision analysis”, 2010, The
Lancet, 376, 9752, 1558-1565
Ochs Ross R. et Col., “Efficacy and Safety of Esketamine Nasal Spray Plus an Oral
Antidepressant in Elderly Patients With Treatment-Resistant Depression—TRANSFORM-3”,
2019, Am. J. Geriatr. Psychiatry, A Paraitre.
Ocker AC, Shah NB, Schwenk ES, Witkowski TA, Cohen MJ, Viscusi ER. Ketamine and cognitive
behavioral therapy for rapid opioid tapering with sustained opioid abstinence: a case report and
1‐year follow‐up. Pain Pract. 2020;20(1):95–100. doi:10.1111/papr.12829
Okamoto N, Nakai T, Sakamoto K, Nagafusa Y, Higuchi T, Nishikawa T. Rapid antidepressant
effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant
depression: comparing ketamine and propofol anesthesia. The journal of ECT. 2010
Sep;26(3):223-7.
Olofsen E, Kamp J, Henthorn TK, van Velzen M, Niesters M, Sarton E, et al. Ketamine psychedelic and
Antinociceptive effects are connected. Anesthesiology. (2022) 136:792–801. doi:
10.1097/ALN.0000000000004176
Olson D., “Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics”,
September 19, 2018, Neuroscience Insights, https://doi.org/10.1177/1179069518800508;
https://journals.sagepub.com/doi/full/10.1177/1179069518800508
Papakostas G, Salloum NC, Hock RS, Jha MK, Murrough JW, Mathew SJ, et al. Efficacy of
esketamine augmentation in major depressive disorder: a metaanalysis. J Clin Psychiatry
2020; 81(4): 19r12889.
Paslakis G, Gilles M, Meyer-Lindenberg A, Deuschle M., “Oral administration of the NMDA
receptor antagonist S-ketamine as add-on therapy of depression: a case series”, 2010,
Pharmacopsychiatry, 43, 1, 33-35.
Payne JE, Chambers R, Liknaitzky P. Combining psychedelic and mindfulness interventions: synergies
to inform clinical practice. ACS Pharmacol Transl Sci. (2021) 4:416–23. doi: 10.1021/acsptsci.1c00034
Pennybaker S. et Col., “Symptomatology and predictors of antidepressant efficacy in
extended responders to a single ketamine infusion’, 2017, Journal of Affective Disorders, 208,
560-566.
Phillips J., “Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant
Depression: A Randomized Controlled Trial”, 2019, Am J Psychiatry, 176, 5, 401-409.
Pizon A, Lynch MJ, Benedict NJ, Yanta JH, Frisch A, Menke NB, et al. Adjunct ketamine use in
the management of severe ethanol withdrawal. Crit Care Med 2018; 46(8): 768–71
Popova V., et Col., “Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined
With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A
Randomized Double-Blind Active-Controlled Study”, 2019, Am J Psychiatry, 176, 6, 428-438.
Pradhan B., et Col., “d-Serine is a potential biomarker for clinical response in treatment of
post-traumatic stress disorder using (R,S)-ketamine infusion and TIMBER psychotherapy: a
pilot study”, 2018, Biochim. Biophys. Acta, Proteins Proteomics, 1866, 831-839.
Price RB, Nock MK, Charney DS, Mathew SJ., “Effects of intravenous ketamine on explicit and
implicit measures of suicidality in treatment-resistant depression”, 2009, Biological
Psychiatry, 65, 5, 522-526.
Price R., et Col., “A novel, brief, fully automated intervention to extend the antidepressant
effect of a single ketamine infusion: a randomized clinical trial”; American Journal of
Psychiatry, 2022, 178, 5, 383-399.
Ragnhildstveit, A.; Jackson, L.K.; Cunningham, S.; Good, L.; Tanner, Q.; Roughan, M.; Henrie-Barrus, P.
Case Report: Unexpected Remission From Extreme and Enduring Bulimia Nervosa With Repeated
Ketamine Assisted Psychotherapy. Front. Psychiatry 2021, 12, 764112. [CrossRef]
Ragnhildstveit, A.; Slayton, M.; Jackson, L.K.; Brendle, M.; Ahuja, S.; Holle, W.; Moore, C.; Sollars, K.;
Seli, P.; Robison, R., “Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence
and Future Directions”, 2022, Brain Sci., 12, 382. 10.3390/brainsci12030382
Rao TS, Andrade C. Innovative approaches to treatment - refractory depression: The
ketamine story. Indian Journal of Psychiatry. 2010 Apr;52(2):97-99.
Rasmussen K., et Col., “Serial infusions of low-dose ketamine for major depression”, 2013,
Journal of Psychopharmacology, 27, 444-450.
Rodrigues N.B., et Col., « A simplified 6-Item clinician administered dissociative symptom
scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions”, J
Affect Disord, 2021, 1, 282:160-164. doi: 10.1016/j.jad.2020.12.119. Epub 2020 Dec 29
Rodriguez C., et Col., “Rapid resolution of obsessions after an infusion of intravenous
ketamine in a patient with treatment-resistant obsessive-compulsive disorder”, 2011, J Clin
Psychiatry., 72, 4, 567–569.
Rodriguez C. et Col., “Randomized controlled crossover trial of ketamine in obsessive-
compulsive disorder: proof-of-concept”, 2013, Neuropsychopharmacology,38,12, 2475-2483.
doi: 10.1038/npp.2013.150.
Rodriguez C., et Col., “Can exposure-based CBT extend the effects of intravenous ketamine in
obsessive-compulsive disorder?”, 2016, J. Clin. Psychiatry, 73, 3, 408-409.
Rolan P., et Col., « The absolute bioavailability of racemic ketamine from a novel sublingual
formulation”, Br J Clin Pharmacol. 2014 Jun; 77(6): 1011–1016.
Romeo B, Choucha W, Fossati P et al (2015) Meta-analysis of short and mid-term efficacy of ketamine
in unipolar and bipolar depression. Psychiatry Res 230(2):682–688
Roquet S., et Col., “The existential through psychodysleptics-A new psychotherapy”, Mexico
City, Mexico, Asociacion Albert Schweitzer, 1971.
Rosa WE, Hope S, Matzo M (2019) Palliative nursing and sacred medicine: a holistic stance on
entheogens, healing, and spiritual care. J Holist Nurs 37(1):100–106
Ross C, Jain R, Bonnett CJ, Wolfson P. High-dose ketamine infusion for the treatment of
posttraumatic stress disorder in combat veterans. Ann Clin Psychiatry. 2019;31(4):271–9.
Rot, M., K. Collins, J. Murrough, A. Perez, D. Reich, D. Charney, and S. Mathew,” Safety and
efficacy of repeated-dose intravenous ketamine for treatment-resistant depression”, 2015,
Biological Psychiatry 67, 2, 139–145. doi:10.1016/j.biopsych.2009.08.038.
Rothberg R., et Col., “Mystical-type expériences occasioned by kétamine mediate its impact
on at-risk drinking: results from a randomized, controlled trial”, 2021, Journal of
Psychopharmacology, 35, 2, 150-158.
Rougemont-Bücking A., “Vampirocen-How structural traumatic dissociation in leading
society into a spiral of violence”, 2023, Pandaemonia Publishing.
Ryan, W., C. Marta, and R. Koek. 2016. Ketamine and depression: A review. In The ketamine
papers, ed. P. Wolfson and G. Hartellius, 199–273. Santa Cruz, CA: MAPS.
Sanacora G., et Col., “A consensus statement on the use of ketamine in the treatment of
mood disorders”, 2017, JAMA Psychiatry, 74, 4, 399-405.
Sanacora G., et Col. « Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive
Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-
Controlled Study”, 2017b, Neuropsychopharmacology. 42, 4, 844-853. doi:
10.1038/npp.2016.224. Epub 2016 Sep 29.
Sappington A., et Col., “Ketamine-facilitated induced anxiety therapy and its effect upon
clients’ reactions to stressful situations”, 1979, J. Clin. Psychol., 35, 425-429.
Şar V. The many faces of dissociation: opportunities for innovative research in psychiatry. Clin
Psychopharmacol Neurosci. 2014 Dec;12(3):171–9.
Sarasso, S. *, Boly, M. *, Napolitani, M., Gosseries, O., Charland-Verville, V., Casarotto, S., ... & Rex, S.
(2015). Consciousness and complexity during unresponsiveness induced by propofol, xenon, and
ketamine. Current Biology, 25(23), 3099-3105. https://doi.org/10.1016/j.cub.2015.10.014
Sartim A.G., et Col., « Co-administration of cannabidiol and ketamine induces antidepressant-like
effects devoid of hyperlocomotor side effects”, Neuropharmacology, 2021, 195, 108679.
Schak K. et Col., “Potential risks of poorly monitored ketamine use in depression treatment”, 2016,
American Journal of Psychiatry, 173, 215-218.
Schatzberg A., “A word to the wise about esketamine”, 2019, American Journal of Psychiatry, 176,
422-424.
Schartner, M. M., Carhart-Harris, R. L., Barrett, A. B., Seth, A. K., & Muthukumaraswamy, S. D. (2017).
Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin.
Scientific reports, 7, 46421. https://doi.org/10.1038/srep46421
Schenberg E., “Psychedelic-assisted psychotherapy: A paradigm shift in psychiatric research and
development”, 2018, Frontiers in Pharmacology, 9, 733.
Schoevers RA, Chaves TV, Balukova SM et al (2016) Oral ketamine for the treatment of pain and
treatment-resistant depression. Br J Psychiatry 208(2):108–113
Schwartz, T.; Trunko, M.E.; Feifel, D.; Lopez, E.; Peterson, D.; Frank, G.K.W.; Kaye, W. A Longitudinal
Case Series of IM Ketamine for Patients with Severe and Enduring Eating Disorders and Comorbid
Treatment-Resistant Depression. Clin. Case Rep. 2021, 9, e03869. [CrossRef]
Scolnick, B.; Zupec-Kania, B.; Calabrese, L.; Aoki, C.; Hildebrandt, T. Remission from Chronic Anorexia
Nervosa With Ketogenic Diet and Ketamine: Case Report. Front. Psychiatry 2020, 11, 763. [CrossRef]
[PubMed)
Shadli S, Kawe T, Martin D, McNaughton N, Neehoff S, Glue P. Ketamine effects on EEG
during therapy of treatment-resistant generalized anxiety and social anxiety. Int J
Neuropsychopharmacol 2018; 21(8): 717–24.
Shah P, McDowell M, Ebisu R, Hanif T, Toerne T. Adjunctive use of ketamine for
benzodiazepine-resistant severe alcohol withdrawal: a retrospective evaluation. J Med
Toxicol 2018; 14(3): 229–36
Sheidegger M., et Col., “Ketamine decreases resting state functional network connectivity in
healthy subjects: Implications for antidepressant drug action”, 2012, PLoS One 7: e44799.
Shiroma P., et Col., “Neurocognitive performance and serial intravenous subanesthesic
ketamine in treatment-resistant depression”, 2014, International Journal of
Neuropsychopharmacology, 17, 11, 1805-1813.
Short, B., Fong, J., Galvez, V., Shelker, W. & Loo, C. K., “Side-effects associated with ketamine
use in depression: a systematic review”, 2018, Lancet Psychiatry 5, 65–78.
Siegal R., “Phencyclidine and ketamine intoxication: A study of four populations of
recreational users.”, National Institute of Drug Abuse Research, 1978, Monograph N°21: 119-
147.
Siegel R., “Phencyclidine and ketamine intoxification: A study of four populations of
recreational users”, 1978, National Institute of Drug Abuse research Monograph #21, 119-
147.
Siegel AN, et al., “Antisuicidal and antidepressant effects of ketamine and esketamine in
patients with baseline suicidality: A systematic review”, J Psychiatr Res,, 2021, 137:426-36.
doi:10.1016/j.jpsychires.2021.03.009 pmid:33774537
Singh J., et Col., “A double-blind, randomized, placebo-controlled, dose frequency study of
intravenous ketamine in patients with treatment-resistant depression”, 2016, American
Journal of Psychiatry, 173, 816-826.
Sleigh, J., Harvey, M., Voss, L. & Denny, B., “Ketamine – More mechanisms of action than just
NMDA blockade”, 2014, Trends Anaesth. Crit. Care, 4, 76–81.
Smith-Apeldoorn SY, Veraart JKE, Kamphuis J et al (2020) Ketamine as an anesthetic, analgesic and
anti-depressant. Tijdschr Psychiatr 62(8):629–639
Sofia RD, Harakal JJ. Evaluation of ketamine HCl for anti-depressant activity. Arch Int Pharmacodyn
Ther. 1975 Mar;214(1):68–74.
Sos P, Klirova M, Novak T, Kohutova B, Horacek J, Palenicek T., “Relationship of ketamine's
antidepressant and psychotomimetic effects in unipolar depression”, 2013, Neuroendocrinol
Lett., 34, 4, 287–293.
Stafford P. Re-creational Uses of LSD. Journal of Psychoactive Drugs. 1985 Oct 1;17(4):219–28.
Stocker K, Hasler G, Hartmann M., “The altered-state-of- consciousness aspect of a feeling of
lightness is reported to be associated with antidepressant benefits by depressed individuals
receiving ketamine infusions: a systematic analysis of Internet video testimonials”,
Psychother Psychosom. 2019:1–2. Epub ahead of print
Strayer R., Nelson L., “Adverse events associated with ketamine for procedural sedation in
adults”, The American Journal of Emergency Medicine, 2008, 26, 9, 985-1028.
Sullivan, P., “Using ketamine to treat addictions”, 2018, Paper presented at the Kriya
Conference, The Nueva School. Hillsborough, CA, November 4.
Sumner RL, Chacko E, McMillan R, et al. « A qualitative and quantitative account of patient’s
experiences of ketamine and its antidepressant properties”, J Psychopharmacol, 2021, Aug, 35, 8,
946-961.
Szymkowicz S., et Col., “A 2-month naturalistic observation of three patients receiving repeat
intravenous ketamine infusions for their treatment-resistant depression”, 2013, Journal of
Affective Disorders, 147, 1-3, 416-420.
Taylor J, Landeros-Weisenberger A, Coughlin C, Mulqueen J, Johnson JA, Gabriel D, et al.
Ketamine for social anxiety disorder: a randomized, placebo-controlled crossover trial.
Neuropsychopharmacology 2018; 43(2): 325–33
Valentine G. et al., “The antidepressant effect of ketamine is not associated with changes in
occipital amino acid neurotransmitter content as measured by [(1)H]-MRS”, 2011, Psychiatry
Res. Neuroimaging,191, 2, 122–127.
Van de Voort J., et Col., « Continuation phase intravenous ketamine in adults with treatment-
resistant depression”, 2016, J Affect Disord, 206, 300-304.
Vollenweider F., et Col., “ Differential psychopathology and pattern of cerebral glucose
utilization produced by (S)- and (R)-ketamine in healthy volunteers using positron emission
tomography (PET)”, 1997, European Neuropsychopharmacology, 7, 25-38.
Vollenweider F. X. & Kometer M., “The Neurobiology of Psychedelic Drugs: Implications for
the Treatment of Mood Disorders”, 2010, Nature Reviews Neuroscience, 11, 9, 642-651.
Wallach, J. 2018. “Pharmacokinetics and pharmacodynamics of ketamine (and Related
Compounds)”. Paper Presented at the Kriya Conference, The Nueva School. Hillsborough, CA,
November 2.
Walsh Z., et Col., “Ketamine for the treatment of mental health and substance use disorders:
comprehensive systematic review” BJPsych Open, 2022, 8, e19, 1-12.
Wan L., et Col., “Ketamine safety and tolerability in clinical trials for treatment-resistant
depression”, 2015, Journal of Clinical Psychiatry, 76, 3, 247-252.
Wang J, Wang Y, Xu X, et al. (2020) Use of various doses of S-ketamine in treatment of depression
and pain in cervical carcinoma patients with mild/moderate depression after laparoscopic total
hysterectomy. Medical Science Monitor 26
Watts R, Day C, Krzanowski J, Nutt D, Carhart-Harris R. Patients’ accounts of increased
“connectedness” and “acceptance” after psilocybin for treatment-resistant depression. Journal of
Humanistic Psychology. 2017;57(5):520–64.
Weber, F., H. Wulf, M. Gruber, and R. Biallas. 2004. S-ketamine and s-norketamine
plasmaconcentrations after nasal and iv administration in anesthetized children.
Paediatr†anaesth 14 (12):983–988.
Weil A., Rosen W., “Chocolate to Morphine: Understanding Mind-Active Drugs”, 1983,
Psychology.
White, P.F.; Ham, J.; Way, W.L.; Trevor, A.J. Pharmacology of Ketamine Isomers in Surgical
Patients. Anesthesiology 1980, 52, 231–239. [CrossRef]
White, P.F.; Schüttler, J.; Shafer, A.; Stanski, D.R.; Horai, Y.; Trevor, A.J. Comparative
Pharmacology of the Ketamine Isomers. Studies in Volunteers. Br. J. Anaesth. 1985, 57,
197–203. [CrossRef]
Wilkinson S, Wright D, Fasula MK, Fenton L, Griepp M, Ostroff RB, et al., “Cognitive behavior
therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant
depression”, 2017a, Psychother. Psychosom., 86, 3, 162–167.
Wilkinson S., et Col., “A survey of the clinical, off-label use of ketamine as a treatment for
psychiatric disorders”, 2017b, American Journal of Psychiatry, 174, 7, 695-696.
Wilkinson ST, Ballard ED, Bloch MH, et al., “The effect of a single dose of intravenous
ketamine on suicidal ideation: a systematic review and individual participant data meta-
analysis”, 2018, Am J Psychiatry, 175, 150–158.
Wilkinson ST, et Col., “Cognitive behavioral therapy to sustain the antidepressant effects of
ketamine in treatment resistant depression: A randomized clinical trial”, 2021, Psychother.
Psychosom., 90, 318-327.
Williams N. et Col., “Attenuation of antidepressants effects of ketamine by opioid receptor
antagonism”, 2018, American Journal of Psychiatry, 175, 1205-1215.
Witt K, Potts J, Hubers A, Grunebaum MF, Murrough JW, Loo C, et al. Ketamine for suicidal
ideation in adults with psychiatric disorders: a systematic review and meta-analysis of
treatment trials. Aust N Z J Psychiatry, 2020; 54(1): 29–45.
Wood DM, Davies S, Puchnarewicz M, Johnston A, Dargan PI, « Acute toxicity associated with the
recreational use of the ketamine derivative methoxetamine. », European journal of clinical
pharmacology, 2011 (PMID 22205276).
Wolfson, P., and G. Hartelius, editors, “The ketamine papers”, 2016, Santa Cruz, CA: MAPS.
Wolfson PE, Andries J, Ahlers D, Whippo M. Ketamine-assisted psychotherapy in adolescents with
multiple psychiatric diagnoses. Front Psych. (2023) 14:1141988. doi: 10.3389/fpsyt.2023.1141988
Wolfson P., Vaid G., “Ketamine-assisted psychotherapy, psychedelic methodologies, and the
impregnable value of the subjective—a new and evolving approach”, Front. Psychiatry, 01
February 2024, Volume 15 - 2024 | https://doi.org/10.3389/fpsyt.2024.1209419
Wong A, Benedict NJ, Armahizer MJ, Kane-Gill SL. Evaluation of adjunctive ketamine to
benzodiazepines for management of alcohol withdrawal syndrome. Ann Pharmacother 2015;
49(1): 14–9.
Xiong J, et al, “The acute antisuicidal effects of single-dose intravenous ketamine and
intranasal esketamine in individuals with major depression and bipolar disorders: A
systematic review and meta-analysis”. J Psychiatr Res, 2021;134:57-68.
doi:10.1016/j.jpsychires.2020.12.038 pmid:33360864
Xu R, Zhan Y and Chen S (2017) Efect of intraoperative single administration of sub-anesthesia
ketamine on breast cancer patients with depression. Biomedical Research (India) 2017(Special Issue
HealthScienceandBioConvergenceTechnologyEdition-II): S552-S556.
Yang C., et Col., “R-ketamine : A rapid onset and sustained antidepressant without
psychotomimetic side effects”, 2015, Translational Psychiatry, 5, e632.
Yao Chou T., & Hann-Chorng K., “ Ketamine cystitis: Its urological impact and management”,
2015, Urological Science, 26, 3, 153-157.
Yensen R., “Group psychotherapy with a variety of hallucinogens”, Septembre 1973,
Conference: Association for Humanistic Psychology Annual Meeting At: Montreal, Quebec,
Canada.
https://www.researchgate.net/publication/261359040_Group_Psychotherapy_with_a_Varie
ty_of_Hallucinogens
Yockey RA. Past-year ketamine use: evidence from a United States population, 2015-2019. J
Psychoactive Drugs. (2023) 55:134–40. doi: 10.1080/02791072. 2022.2058896
Yovell Y., et Col., “Ultra-Low-Dose Buprenorphine as a Time-Limited Treatment for Severe
Suicidal Ideation: A Randomized Controlled Trial”, 2016, AM J Psychiatry, 73, 5: 491-498.
Zacharias N. et Col., « Ketamine effects on default mode network activity and vigilance: A
randomized, placebo-controlled crossover simultaneous fMRI/EEG study”, Hum Brain Mapp.,
2020, 41, 1, 107-119.
Zanos P., et Col., “NMDAR inhibition-independent antidepressant actions of ketamine
metabolites », 2016, Nature, 533, 481-486.
Zanos P., et Col., “Ketamine and Ketamine Metabolite Pharmacology: Insights into
Therapeutic Mechanisms”, Pharmacol Rev , 2018, Jul;70(3):621-660. doi: 10.1124/pr.117.015198.
Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji
HK., “A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major
depression”, 2006, Archives of General Psychiatry, 63, 8, 856-64.
Zarate C.A. et Col., “Replication of ketamine’s antidepressant efficacy in bipolar depression: a
randomized controlled add-on trial”, 2012, Biol. Psychiatry, 71, 11, 939-946.
Zarate, C., R. Duman, G. Liu, S. Sartori, J. Quiroz, and H. Murck., “ New paradigms for
treatment-resistant depression”, 2013, Annals of the New York Academy of Sciences 1292,
1, 21–31. doi:10.1111/nyas.12223.
Zarate et Col., « A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate
Channel Blocker in Major Depression”, 2013b, Biological Psychiatry,74, 4 , 257-264
Zarate CA Jr, Niciu MJ. 2015 ketamine for depression: evidence, challenges and promise. World
Psychiatry. (2015) 14:348–50. doi: 10.1002/wps.20269
Zdanys K, Tampi RR. A systematic review of off-label uses of memantine for psychiatric
disorders. Prog Neuropsychopharmacol Biological Psychiatry. 2008 Aug
Zhan Y., et Col., “A preliminary study of anti-suicidal efficacy of repeated ketamine infusions
in depression with suicidal ideation”, 2019, Journal of Affective Disorders, 251, 205-212.
Zhang J., et Col., “R (-) ketamine shows greater potency and longer lasting antidepressant
effects than S (+) ketamine”, 2014, Pharmacology Biochemistry Behavior, 116, 137-141.
Zheng W. et Col., “Investigation of medical effect of multiple ketamine infusions on patients
with major depressive disorder”, 2019, Journal of Psychopharmacology, 33, 4, 494-501
Zdanys K, Tampi RR. A systematic review of off-label uses of memantine for psychiatric
disorders. Prog Neuropsychopharmacol Biological Psychiatry. 2008 Aug
Zhang J., et Col., “R (-) ketamine shows greater potency and longer lasting antidepressant
effects than S (+) ketamine”, 2014, Pharmacology Biochemistry Behavior, 116, 137-141.
Zheng W. et Col., “Investigation of medical effect of multiple ketamine infusions on patients
with major depressive disorder”, 2019, Journal of Psychopharmacology, 33, 4, 494-501.
Zunszain PA, Horowitz MA, Cattaneo A, Lupi MM, Pariante CM. Ketamine: synaptogenesis,
immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant
properties. Mol Psychiatry. 2013;18(12):1236–1241. doi:10.1038/mp.2013.87
In Wolfson, P., and G. Hartelius, editors, “The ketamine papers”, 2016, Santa Cruz, CA:
MAPS.
In Grob C., Grigsby J. (Eds.), “Handbook of Medical Hallucinogens”, 2021, Guilford Press.
Les psychédéliques regroupent plusieurs substances psychoactives d'origine naturelle ou synthétique. Elles sont largement reconnus pour leur haut potentiel thérapeutique dans le cadre d'une psychothérapie assistée par psychédélique (PAP) pour le traitement de l’anxiété, de la dépression, de nombreuses dépendances, du trouble de stress post-traumatique (PTSD), ou encore de la détresse anxio-dépressive de fin de vie. Ce haut potentiel thérapeutique représente à lui seul une révolution en cours dans le domaine de la santé mentale et du bien-être psychique.
L’agence gouvernementale américaine (Food and Drug Administration) chargée de protéger la santé publique a attribué le statut de thérapie révolutionnaire à ces 3 substances psychédéliques:
La recherche scientifique a démontré l'utilité, l'innocuité (le caractère sans danger) et l'extraordinaire efficacité des thérapies psychédéliques pour de nombreuses indications.
La PAP est une forme innovante de psychothérapie, intégrant l'utilisation d'une substance psychoactive comme la psilocybine, ou encore la MDMA. Elle permet d'induire une profonde expérience thérapeutique de reconnexion à soi-même, et à “plus grand que soi-même”, facilitant ainsi une guérison transformatrice et durable. Cette approche constitue une puissante médecine globale intégrant toutes les dimensions humaines (physique, psychique, émotionnelle et spirituelle).
Dans un contexte de crise majeure en matière de santé mentale à l'échelle globale, touchant tous les milieux sociaux et toutes les communautés, incluant le monde du travail, la PAP s'avère extrêmement prometteuse pour son efficacité supérieure aux traitements classiques pour les indications suivantes : anxiété, burnout, plusieurs types de dépressions et de dépendances (alcool, tabac, opioïdes, cocaïne, etc.), troubles alimentaires, TOC, troubles de stress post-traumatique (PTSD), détresse de fin de vie dans le cadre d'une maladie menaçant le pronostic vital, et peut-être certaines maladies neurodégénératives (Parkinson, Alzheimer).
Certains praticiens du secteur, médecins, psychothérapeutes et chercheurs, n'hésitent donc pas à parler de "psychopharmacologie disruptive" ou encore de "turbo thérapie". Ce concept repose sur l'utilisation de protocoles thérapeutiques ciblant la substance psychédélique la plus adaptée à chaque patient, afin de l'accompagner vers une guérison transformatrice et durable, en tenant compte de son unicité (de son histoire unique, de ses traumatismes, etc.).
Ce nouveau paradigme psychothérapeutique permet d’accéder à une profonde reconnexion à soi, aux autres et au monde, une meilleure capacité d’acceptation du parcours de vie, une plus grande résilience, et une saine adaptation dans un monde en perpétuel changement.
Important : l'efficacité de la PAP - aussi communément appelée médecine psychédélique - repose autant sinon plus sur le niveau d'expérience et de compétence de l’équipe de praticiens et co-thérapeutes, que sur le choix du protocole et de la substance utilisés.
Il est aussi important de garder en tête que l'ensemble des substances psychédéliques sont, et resteront, des médicaments réglementés, soumis à un cadre d'usage légal en évolution rapide, facilitant ainsi l'accès à de nouveaux types de traitements.
La psychothérapie assistée par kétamine (KAP) est déjà proposée par plusieurs cliniques spécialisées au Canada, aux États-Unis et en Europe. De nombreux essais cliniques sont actuellement en cours afin de faire avancer la recherche, et ainsi permettre aux autorités gouvernementales (notamment Santé Canada) d’autoriser de nouveaux traitements pour une plus grande diversité d’indications dans le futur. À titre d'exemple, Santé Canada a autorisé en 2022 l’utilisation de la psilocybine et de la MDMA, dans le cadre de son Programme d’Accès Spécial (PAS). Ce changement réglementaire permet à certains patients d’accéder à une psychothérapie pleinement adaptée à leurs besoins dans le cadre d’un programme compassionnel.
ENTEA prévoit d’offrir prochainement des thérapies d'intégration et des services de psychothérapie assistée par psychédélique.
Contactez-nous pour obtenir plus d'informations.